3 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
29 Feb 24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
4:16pm
enrollment in pivotal Phase 3 study in SMA: In September 2023, the Company announced that it had completed enrollment in RESILIENT, a pivotal Phase 3
8-K
EX-99.1
BHVN
Biohaven Ltd.
14 Nov 23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
4:26pm
effects. Separately, we completed enrollment in RESILIENT, our Phase 3 pivotal study of taldefgrobep alfa in SMA in record time, thanks to our … that it had completed enrollment in RESILIENT, a pivotal Phase 3 study designed to evaluate the efficacy and safety of taldefgrobep as adjunctive therapy
8-K
EX-99.1
BHVN
Biohaven Ltd.
27 Sep 23
Regulation FD Disclosure
6:58am
past success of experienced team and a resilient focus on creating value for patients and shareholders
PRECLINICAL PHASE 1 PHASE 2 PHASE 3 FILED ION … exhibit several relevant epigenetic changes linked to Kv73 Preclinical evidence for manic and depressive poles ü Mice who upregulate Kv7 are resilient
- Prev
- 1
- Next